Nuvalent, Inc. (NUVL)
Largest Insider Buys in Sector
NUVL Stock Price History Chart
NUVL Stock Performance
About Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent …
Insider Activity of Nuvalent, Inc.
Over the last 12 months, insiders at Nuvalent, Inc. have bought $0 and sold $332.16M worth of Nuvalent, Inc. stock.
On average, over the past 5 years, insiders at Nuvalent, Inc. have bought $52.71M and sold $125.08M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 650,000 shares for transaction amount of $21.77M was made by Flynn James E (director) on 2022‑11‑03.
List of Insider Buy and Sell Transactions, Nuvalent, Inc.
| 2024-12-16 | Sale | President and CEO | 27,000 0.0379% | $86.61 | $2.34M | -3.66% | ||
| 2024-12-11 | Sale | director | 1.25M 1.6417% | $88.00 | $110M | -7.23% | ||
| 2024-11-29 | Sale | Chief Financial Officer | 10,000 0.0139% | $95.79 | $957,940 | -3.51% | ||
| 2024-11-25 | Sale | director | 2,000 0.0028% | $96.22 | $192,443 | -1.98% | ||
| 2024-11-15 | Sale | President and CEO | 27,000 0.0375% | $87.94 | $2.37M | +7.88% | ||
| 2024-11-01 | Sale | Chief Development Officer | 5,000 0.0071% | $88.60 | $442,980 | +5.05% | ||
| 2024-10-31 | Sale | Chief Financial Officer | 10,000 0.0144% | $89.19 | $891,879 | +5.85% | ||
| 2024-10-28 | Sale | director | 2,000 0.0026% | $91.73 | $183,468 | 0.00% | ||
| 2024-10-22 | Sale | * Director by deputization | 1M 1.3662% | $97.75 | $97.75M | 0.00% | ||
| 2024-10-15 | Sale | President and CEO | 27,000 0.0392% | $102.28 | $2.76M | -8.48% | ||
| 2024-10-01 | Sale | Chief Development Officer | 5,000 0.0072% | $101.74 | $508,718 | -8.49% | ||
| 2024-09-30 | Sale | Chief Financial Officer | 10,000 0.0143% | $101.06 | $1.01M | -7.83% | ||
| 2024-09-23 | Sale | director | 2,000 0.0029% | $102.75 | $205,500 | -7.55% | ||
| 2024-09-16 | Sale | Chief Scientific Officer | 32,795 0.0446% | $98.92 | $3.24M | -15.37% | ||
| 2024-09-16 | Sale | Chief Legal Officer | 8,000 0.0106% | $96.47 | $771,798 | -15.37% | ||
| 2024-09-09 | Sale | Chief Legal Officer | 3,000 0.0046% | $88.18 | $264,546 | +6.17% | ||
| 2024-09-03 | Sale | Chief Development Officer | 5,000 0.0078% | $84.43 | $422,146 | +12.76% | ||
| 2024-08-30 | Sale | Chief Financial Officer | 10,000 0.0153% | $84.23 | $842,349 | +10.76% | ||
| 2024-08-26 | Sale | director | 2,000 0.0031% | $84.46 | $168,914 | +11.90% | ||
| 2024-08-23 | Sale | Chief Scientific Officer | 10,500 0.0162% | $85.08 | $893,340 | +10.28% |
Insider Historical Profitability
| Flynn James E | * Director by deputization | 8670512 12.203% | $82.65 | 3 | 1 | +13.74% |
| Hack Andrew A. F. | director | 1447267 2.0369% | $82.65 | 2 | 2 | +4.5% |
Institutional Investor Ownership
| Deerfield Management | $1.5B | 30.97 | 19.99M | 0% | +$0 | 3.66 | |
| Fidelity Investments | $660.41M | 13.62 | 8.79M | +0.8% | +$5.24M | 0.04 | |
| Paradigm BioCapital Advisors LP | $313.71M | 6.47 | 4.18M | +8.29% | +$24.02M | 11.38 | |
| The Vanguard Group | $256.21M | 5.29 | 3.41M | +2.16% | +$5.42M | 0.01 | |
| Perceptive Advisors | $209.01M | 4.31 | 2.78M | -4.61% | -$10.1M | 0.14 |